Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. (Q30361848)

6 October 2017

Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. (English)

1 reference

6 October 2017

phase II clinical trial

0 references

author

Antonio Omuro

18

1 reference

6 October 2017

Craig P Nolan

8

0 references

Igor T Gavrilovic

Igor Gavrilovic

10

0 references

Thomas J Kaley

Thomas J Kaley

1

0 references

Lisa M DeAngelis

Lisa M DeAngelis

9

0 references

Patrick Y Wen

2

Patrick Wen

1 reference

6 October 2017

13

Eudocia Quant Lee

1 reference

6 October 2017

17

Lauren E Abrey

1 reference

6 October 2017

David Schiff

3

1 reference

6 October 2017

Keith Ligon

4

1 reference

6 October 2017

Sam Haidar

5

1 reference

6 October 2017

Sasan Karimi

6

1 reference

6 October 2017

Andrew B Lassman

7

1 reference

6 October 2017

Andrew Norden

11

1 reference

6 October 2017

Jan Drappatz

12

1 reference

6 October 2017

Benjamin Purow

14

1 reference

6 October 2017

Scott R Plotkin

15

1 reference

6 October 2017

Tracy Batchelor

16

1 reference

6 October 2017

6 August 2014

1 reference

6 October 2017

1 reference

6 October 2017

17

1 reference

6 October 2017

1

1 reference

6 October 2017

116-121

1 reference

CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010.

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483051

Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483051

Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483051

Atypical and anaplastic meningiomas treated with bevacizumab.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483051

Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483051

Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483051

Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483051

Angiogenesis in meningiomas

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483051

Medical therapies for meningiomas

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483051

A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483051

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483051

Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483051

Advances in meningioma therapy

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483051

Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483051

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483051

Salvage chemotherapy with CPT-11 for recurrent meningioma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483051

Temozolomide for treatment-resistant recurrent meningioma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483051

PDGF receptors as cancer drug targets

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483051

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483051

Evidence for mitogen-associated protein kinase activation and transduction of mitogenic signals by platelet-derived growth factor in human meningioma cells

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483051

Antiestrogenic therapy of meningiomas--a pilot study

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483051

Human meningiomas co-express platelet-derived growth factor (PDGF) and PDGF-receptor genes and their protein products

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483051

Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483051

A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study

3 June 2018

1 reference

https://api.crossref.org/works/10.1093/NEUONC/NOU148

Different distribution of c-myc and MIB-1 positive cells in malignant meningiomas with reference to TGFs, PDGF, and PgR expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/NEUONC/NOU148

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/NEUONC/NOU148

Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/NEUONC/NOU148

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483051

Expression of PDGF and its receptor as well as their relationship to proliferating activity and apoptosis of meningiomas in human meningiomas

26 November 2018

1 reference

12 December 2020

Expression of PDGF β-receptors in human meningioma cells

1 reference

12 December 2020

Platelet-derived growth factor expression and stimulation in human meningiomas

1 reference

12 December 2020

Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor

1 reference

12 December 2020

The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B

1 reference

12 December 2020

Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma

1 reference

12 December 2020

Identifiers

DOI

10.1093/NEUONC/NOU148

1 reference

6 October 2017

1 reference

6 October 2017

PubMed publication ID

25100872

1 reference